## 1 Introduction  
Migraine is one of the most common neurological illnesses, characterized by episodic, severe headache attacks, typically lasting between 4 to 72 h. It impacts approximately 14-15% of the worldwide population, including two to three times more females than males [1, 2]. Headaches often occur in adults aged 20 to 50, but children and adolescents are also subjected [2]. In addition to a higher incidence of migraines, women declare longer attack durations and recovery times, as well as greater disability [3]. This gender disparity suggests that hormonal factors, particularly estrogen levels, play a significant role in migraine, as women often report changes in their headache patterns concerning their menstrual cycle [2, 4]. Migraine is identified by additional symptoms such as phonophobia and photophobia, episodes of vomiting, diarrhea, and nausea [5]. Moreover, approximately 15-30% of people suffering from migraine experience headaches with an aura, which is a neurological phenomenon characterized by sensory, visual, and occasionally language disorders [6]. This increases the risk of many conditions, such as stroke and other cardiovascular diseases [7]. It was also observed that people with chronic migraines complain about insomnia and fatigue. Treatments for such symptoms include taking acute and preventive drugs. Multiple medications are effective in the immediate management of migraine episodes, e.g., non-steroidal anti-inflammatory drugs (NSAIDs, i.e., naproxensodium, ibuprofen, ketoprofen, and diclofenac sodium), analgesics (i.e., paracetamol), triptans (sumatriptan, zolmitriptan, eletiptan, and rizatriptan), and calcitonin gene-related peptide (CGRP) receptor antagonists [8]. Conventional drug dosage forms (tablets, capsules, granules, etc.) are characterized by various limitations. The main concern is the potential for side effects such as renal dysfunction, gastrointestinal bleeding, and cardiovascular events [9]. It could be problematic in the case of taking drugs over an extended period at high doses. Many active pharmaceutical ingredients often have low solubility as well as poor absorption ability from the site of administration [10]. When drugs are ingested, the acidic conditions in the digestive system, along with the presence of digestive enzymes, can lead to their degradation before they can reach the bloodstream [11]. Given this, there is a necessity to develop an optimized drug delivery platform that will carry and liberate the pharmaceuticals at a controlled rate and maintain the desired therapeutic effect for a longer time [12; 13]. Controlled and sustainable drug release platforms are one of the most rapidly advancing science topics due to their influence on human health. They can extend the pharmacological action duration of drugs, reduce the frequency of dosage, and consequently prevent the occurrence of adverse effects [14; 15]. So far, a wide variety of ordered mesoporous silica, carbon materials, polymeric, and hybrid structures have been designed as targeted and controlled drug delivery systems [16; 17; 18; 19]. Among them, metal-organic frameworks (MOFs), an interesting class of crystalline materials developed by linking molecular building blocks into a predetermined, extended periodic structure, found biomedical applications [20]. They have been investigated for drug delivery in recent years due to their high adsorption capacity, biocompatibility, and biodegradation [21]. Additionally, they are able to reach precise and sustained drug release. One of the most popular MOFs for drug delivery applications is those synthesized at the Lavoisier Institute known as MIL (MIL--Materiaux de l'Institut Lavoisier) materials [22]. They consist of iron nodes, naturally present in the body, which reduces their toxicity [23]. This group includes, i.e., MIL-88A, MIL-101(Fe), MIL-100(Fe), and MIL-53(Fe). [PERSON] and co-workers [24] successfully used MIL-101(Fe) functionalized with various polyamines as a naproxen sodium carrier.